Previous 10 | Next 10 |
2023-05-31 11:07:40 ET Aquestive Therapeutics released clinical data from recent pilot studies on Anaphylm, a sublingual film for the treatment of anaphylaxis. The studies showed that Anaphylm achieved a maximum blood concentration (Tmax) in a median time of 10 minutes, ranging from 5...
Time to maximum blood concentration (median Tmax) for Anaphylm was 10 minutes with a range of 5 to 20 minutes Early drug exposure at 10 minutes (partial area under the curve, or pAUC 0-10min ) for Anaphylm was similar to Auvi-Q® (epinephrine injection) auto-injector 0.3mg a...
2023-05-12 13:14:08 ET Gainers: GSI Technology ( GSIT ) +149% . ARS Pharmaceuticals ( SPRY ) +80% . Zapp Electric Vehicles Group Limited ( ZAPP ) +42% . AirSculpt Technologies ( AIRS ) +39% . Blue Bird Corporation ( BLBD ) +34% ....
2023-05-03 10:35:06 ET Aquestive Therapeutics, Inc. (AQST) Q1 2023 Earnings Conference Call May 03, 2023, 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, C...
2023-05-02 17:11:24 ET Aquestive Therapeutics press release ( NASDAQ: AQST ): Q1 GAAP EPS of $0.11. Revenue of $11.13M (-9.3% Y/Y) beats by $1.19M . Now sees FY 2023 revenue of $42M to $46M from $37M to $41M previously. The consensus estimate is $39.06M. For ...
Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™ Raises full year 2023 revenue and non-GAAP adjusted EBITDA guidance Reaffirms commitment to pursue early market access for Libervant™ (diazep...
2023-04-20 10:42:57 ET Aquestive Therapeutics ( NASDAQ: AQST ) disclosed that the FDA has conditionally sanctioned Anaphylm as the proposed brand name for AQST-109, which is used to treat severe allergic reactions, particularly anaphylaxis. The proprietary name Anaphylm was de...
WARREN, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative produc...
WARREN, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative produ...
2023-03-29 09:15:13 ET Aquestive Therapeutics ( NASDAQ: AQST ) expanded its exclusive license and supply agreement with Atnahs Pharma UK (Pharmanovia) for seizure therapy Libervant (diazepam) Buccal Film. The expanded agreement will cover the rest of the world, e...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...